WO2001066565A3 - In vivo production of cyclic peptides - Google Patents

In vivo production of cyclic peptides Download PDF

Info

Publication number
WO2001066565A3
WO2001066565A3 PCT/US2001/007162 US0107162W WO0166565A3 WO 2001066565 A3 WO2001066565 A3 WO 2001066565A3 US 0107162 W US0107162 W US 0107162W WO 0166565 A3 WO0166565 A3 WO 0166565A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclic peptides
vivo production
vivo
production
inteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007162
Other languages
French (fr)
Other versions
WO2001066565A9 (en
WO2001066565A2 (en
Inventor
Todd M Kinsella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Priority to EP01920220A priority Critical patent/EP1263777A2/en
Priority to AU2001247296A priority patent/AU2001247296A1/en
Publication of WO2001066565A2 publication Critical patent/WO2001066565A2/en
Publication of WO2001066565A3 publication Critical patent/WO2001066565A3/en
Anticipated expiration legal-status Critical
Publication of WO2001066565A9 publication Critical patent/WO2001066565A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo.
PCT/US2001/007162 2000-03-06 2001-03-06 In vivo production of cyclic peptides Ceased WO2001066565A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01920220A EP1263777A2 (en) 2000-03-06 2001-03-06 In vivo production of cyclic peptides
AU2001247296A AU2001247296A1 (en) 2000-03-06 2001-03-06 In vivo production of cyclic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18713000P 2000-03-06 2000-03-06
US60/187,130 2000-03-06

Publications (3)

Publication Number Publication Date
WO2001066565A2 WO2001066565A2 (en) 2001-09-13
WO2001066565A3 true WO2001066565A3 (en) 2002-07-25
WO2001066565A9 WO2001066565A9 (en) 2009-03-26

Family

ID=22687720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007162 Ceased WO2001066565A2 (en) 2000-03-06 2001-03-06 In vivo production of cyclic peptides

Country Status (4)

Country Link
US (3) US7105341B2 (en)
EP (1) EP1263777A2 (en)
AU (1) AU2001247296A1 (en)
WO (1) WO2001066565A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091966A1 (en) * 1999-08-30 2004-05-13 Martin Zeidler Polypeptide regulation by conditional inteins
US7252952B2 (en) * 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
US20030219723A1 (en) * 2002-05-20 2003-11-27 Lu Henry H. Compositions and methods for screening and identifying anti-HCV agents
US20060275832A1 (en) * 2002-08-30 2006-12-07 Esteban Masuda Methods of screening cyclic peptides and identifying targets therefor
WO2005115433A2 (en) 2004-05-24 2005-12-08 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
JP2008516979A (en) * 2004-10-14 2008-05-22 リゲル ファーマシューティカルズ インコーポレーティッド Heterocyclic inhibitors of IRES-mediated translation and uses thereof
EP1942947A4 (en) * 2005-10-04 2010-09-01 Res Foundation Of The State Un FIBRONECTIN POLYPEPTIDES AND METHODS OF USE
US20100143972A1 (en) * 2006-12-14 2010-06-10 Horswill Alexander R Method of Making Cyclic Polypeptides with Inteins
EP2990411B1 (en) * 2007-03-26 2017-05-03 The University of Tokyo Process for synthesizing cyclic peptide compound
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
EP2224955A4 (en) 2007-11-27 2011-02-16 Univ British Columbia COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ARTHRITIS
US20110064717A1 (en) * 2009-08-20 2011-03-17 Ramot At Tel-Aviv University Ltd. Homing endonuclease genes and their targets
CA2776990A1 (en) * 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
JP5725467B2 (en) * 2010-08-27 2015-05-27 国立大学法人 東京大学 New artificial translation synthesis system
CN105473721A (en) * 2013-03-11 2016-04-06 先锋国际良种公司 Methods and compositions employing a sulfonylurea-dependent stabilization domain
US12359192B2 (en) 2013-12-23 2025-07-15 University Of Rochester Methods and compositions for display of macrocyclic peptides
WO2015100277A2 (en) 2013-12-23 2015-07-02 University Of Rochester Methods and compositions for ribosomal synthesis of macrocyclic peptides
JP6653979B2 (en) * 2015-07-03 2020-02-26 フーナン ゾンセン ペプリブ バイオテック カンパニー リミテッド Construction method of peptide library
CN116217657A (en) 2016-05-27 2023-06-06 辛赛克斯公司 protein interface
CA3040467C (en) 2016-10-14 2023-10-31 Neomatrix Therapeutics, Inc Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
PT3596106T (en) * 2017-04-26 2021-09-10 Hunan Zonsen Peplib Biotech Co Ltd Peptide library constructing method
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
KR102125888B1 (en) * 2018-10-30 2020-06-23 명지대학교 산학협력단 Novel cyclic peptide, manufacturing method of the same anc use of the same
KR102675750B1 (en) * 2019-09-24 2024-06-18 엠브릭스 주식회사 Nano-perforator having enhanced antiviral activity
GB201918693D0 (en) * 2019-12-18 2020-01-29 Univ Southampton Peptide
WO2024181806A1 (en) * 2023-02-28 2024-09-06 건국대학교 산학협력단 Protein cyclization system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036093A2 (en) * 1998-12-18 2000-06-22 The Penn State Research Foundation Intein-mediated cyclization of peptides
WO2001057183A2 (en) * 2000-02-04 2001-08-09 New England Biolabs, Inc. Method for producing circular or multimeric protein species in vivo or in vitro and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244222A1 (en) * 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6531316B1 (en) * 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US20030068649A1 (en) * 2000-09-14 2003-04-10 Doberstein Stephen K. Methods and compositions for the construction and use of fusion libraries
JP2005518334A (en) * 2001-06-08 2005-06-23 メタファー・ファーマシューティカルズ・インコーポレイテッド Conformationally constrained peptide, chiral azacrown and peptide mimetic libraries and methods for their production
US7723018B2 (en) * 2002-08-30 2010-05-25 Rigel Pharmaceuticals, Incorporated Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
US20040053324A1 (en) * 2002-08-30 2004-03-18 Brian Wong Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036093A2 (en) * 1998-12-18 2000-06-22 The Penn State Research Foundation Intein-mediated cyclization of peptides
WO2001057183A2 (en) * 2000-02-04 2001-08-09 New England Biolabs, Inc. Method for producing circular or multimeric protein species in vivo or in vitro and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EVANS THOMAS C JR ET AL: "Accelerated publication: Protein trans-splicing and cyclization by a naturally split intein from the dnaE gene of Synechocystis species PCC6803.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 13, 31 March 2000 (2000-03-31), pages 9091 - 9094, XP002187846, ISSN: 0021-9258 *
EVANS THOMAS C JR ET AL: "The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18359 - 18363, XP002925640, ISSN: 0021-9258 *
SCOTT CHARLES P ET AL: "Production of cyclic peptides and proteins in vivo.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 24, 23 November 1999 (1999-11-23), Nov. 23, 1999, pages 13638 - 13643, XP002187845, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20050233456A1 (en) 2005-10-20
US20070105140A1 (en) 2007-05-10
US7105341B2 (en) 2006-09-12
US20050158820A1 (en) 2005-07-21
AU2001247296A8 (en) 2009-04-23
US7208571B2 (en) 2007-04-24
WO2001066565A9 (en) 2009-03-26
EP1263777A2 (en) 2002-12-11
AU2001247296A1 (en) 2001-09-17
WO2001066565A2 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2001066565A3 (en) In vivo production of cyclic peptides
WO2004019890A3 (en) In vivo production of cyclic peptides for inhibiting protein-protein interaction
WO2001058412A3 (en) Extracts from residues left in the production of wine
MXPA02004666A (en) Recombinant gelatins.
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
IL161229A0 (en) Methods and compositions relating to restricted expression lentiviral vectors and their applications.
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
MXPA03011793A (en) Interferon formulations.
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
AU144678S (en) Bottle
ID30299A (en) OKSAZOLIDINON DERIVES, THE PROCESS OF MAKING IT AND THE PHARMACY COMPOSITION THAT CONTAINS IT
WO2002085923A3 (en) In vivo incorporation of unnatural amino acids
AU2002315200A1 (en) Production metering and well testing system background of the invention
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
AU2002348151A1 (en) Viral vector production methods and compositions
PL1668001T3 (en) Substituted heteroaryl benzofuran acids
DE60120712D1 (en) Kallikrein gen
WO2002066653A3 (en) Procaryotic libraries and uses
WO2003074546A3 (en) Streptavidin-binding peptide
WO2004007664A3 (en) Nucleic acid vectors
WO2002022553A3 (en) Non-natural basic amino acids, their preparation and use
WO2002102324A3 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2001920220

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920220

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP